Search
Dexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of DB00448, which is ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPradefovir mesylate
go.drugbank.com/drugs/DB05478InvestigationalPradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver.
SN-38
go.drugbank.com/drugs/DB05482Investigational7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studyin...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTechnetium Tc-99m ciprofloxacin
go.drugbank.com/drugs/DB05488Experimental99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal absce...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesGTS-21
go.drugbank.com/drugs/DB05708InvestigationalGTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athe...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesGPI-1485
go.drugbank.com/drugs/DB05814InvestigationalGPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without a...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSeletracetam
go.drugbank.com/drugs/DB05885InvestigationalSeletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppressio...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT1A receptors and as an antagonist at ser...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates